A rare adverse effect while treating lung adenocarcinoma
More details
Hide details
Pulmonology Department, Agios Savvas Oncology Hospital, Athens, Greece
Gastroenterology Department, Agios Savvas Oncology Hospital, Athens, Greece
Corresponding author
Georgios Politis   

Pulmonary 171 Alexandras Ave., 115 22 Athens, Greece
Pneumon 2015;28(3):262-265
Rhabdomyolysis is a syndrome resulting from acute skeletal muscle necrosis, with subsequent massive release of muscle cell components into the circulation. Although the pathophysiology as well as the clinical aspects of rhabdomyolysis have been quite well investigated, the physician should be alert in case a patient presents with the syndrome, as it may be complicated with acute kidney injury which increases mortality. In addition, the causes of rhabdomyolysis are multiple, with drugs being responsible most of the times. In the field of oncology, the complexity of patients’ symptoms and the continuous introduction of new medicines make the diagnosis of any clinical entity challenging. The oncologist should always include rhabdomyolysis in the differential diagnosis of related symptoms (the classic triad of myalgias, muscle weakness and urine hyperpigmentation). Early treatment decreases the duration of rhabdomyolysis and may prevent acute kidney injury. Bevacizumab is an anti-VEGF agent indicated in the treatment of numerous neoplastic diseases. Rhabdomyolysis is not usual after chemotherapy or monoclonal antibody administration. We observed and here present a case of rhabdomyolysis after bevacizumab therapy in a patient with nonsmall cell lung cancer and we subsequently review the aspects of rhabdomyolysis. Our aim is to alert physicians treating oncology patients in rhabdomyolysis, as a rare adverse effect of anticancer drugs.
Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013; 144:1058-65.
Vanholder R, et al. Rhabdomyolysis. J Am Soc Nephrol 2000; 11:1553–61.
Huang MS, Tsai JR, Shen MC, Chou SH, Yang CJ. Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. Lung Cancer 2012;76:491-2.
Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol 2002;70:320-3.
Vicente E, et al. Acute rhabdomyolysis as a complication of paclitaxel–gemcitabine chemotherapy for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2009;145:226.
Stoyianni A, et al. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 2011;97:252-5.
Valiyil R, Christopher-Stine L. Drug-related Myopathies of Which the Clinician Should Be Aware. Curr Rheumatol Rep 2010;12:213–20.
Ramamoorthy SK. Unusual reaction to Rituximab with intravascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. Leuk Lymphoma 2006;47:747-50.
Ruggeri EM et al. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases. Annals of Oncol 2010;21:1926-7.
Hurwitz HI et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist 2013;18:1004-12.
Journals System - logo
Scroll to top